Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel Free SXTPW Stock Alerts

60 Degrees Pharmaceuticals (SXTPW) Competitors

60 Degrees Pharmaceuticals logo
$0.03 0.00 (0.00%)
As of 08/14/2026
Compare

SXTPW vs. BFRIW, CALA, CINGW, CMRAW, and CDTTW

Should you buy 60 Degrees Pharmaceuticals stock or one of its competitors? 60 Degrees Pharmaceuticals's main competitors and comparable companies include Biofrontera (BFRIW), Calithera Biosciences (CALA), Cingulate (CINGW), Comera Life Sciences (CMRAW), and Conduit Pharmaceuticals (CDTTW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 60 Degrees Pharmaceuticals compare to Biofrontera?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Biofrontera had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 3 mentions for Biofrontera and 2 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.93 beat Biofrontera's score of 0.96 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
60 Degrees Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Biofrontera
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Biofrontera N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Summary

Biofrontera beats 60 Degrees Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Calithera Biosciences?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Calithera Biosciences (NASDAQ:CALA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

60 Degrees Pharmaceuticals has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Calithera Biosciences N/A N/A N/A

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Calithera Biosciences. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Calithera Biosciences. 60 Degrees Pharmaceuticals' average media sentiment score of 1.93 beat Calithera Biosciences' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Calithera Biosciences Neutral

Summary

60 Degrees Pharmaceuticals beats Calithera Biosciences on 3 of the 3 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Cingulate?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 2 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 1.93 beat Cingulate's score of 1.44 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Cingulate Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Cingulate N/A N/A N/A

Summary

60 Degrees Pharmaceuticals beats Cingulate on 2 of the 2 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Comera Life Sciences?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Comera Life Sciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Comera Life Sciences. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Comera Life Sciences. 60 Degrees Pharmaceuticals' average media sentiment score of 1.93 beat Comera Life Sciences' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
60 Degrees Pharmaceuticals Very Positive
Comera Life Sciences Neutral

Summary

60 Degrees Pharmaceuticals beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Conduit Pharmaceuticals?

Conduit Pharmaceuticals (NASDAQ:CDTTW) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Company Net Margins Return on Equity Return on Assets
Conduit PharmaceuticalsN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Conduit PharmaceuticalsN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Conduit Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 1.93 beat Conduit Pharmaceuticals' score of 1.87 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Conduit Pharmaceuticals Very Positive
60 Degrees Pharmaceuticals Very Positive

Summary

60 Degrees Pharmaceuticals beats Conduit Pharmaceuticals on 3 of the 3 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTPW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTPW vs. The Competition

Export
Metric60 Degrees PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$11.92B$7.02B$13.06B
Dividend YieldN/A2.70%2.57%10.45%
P/E RatioN/A779.99271.2725.33
Price / SalesN/A749.47588.5578.45
Price / CashN/A66.4570.4850.90
Price / BookN/A11.6012.926.25
Net IncomeN/A$2.77B$3.45B$347.82M
7 Day PerformanceN/A0.14%1.16%1.08%
1 Month PerformanceN/A0.06%1.37%0.82%
1 Year PerformanceN/A145.15%62.53%20.99%

60 Degrees Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/A-63.9%$0.00$1.00MN/A2
BFRIW
Biofrontera
N/A$0.02
-22.4%		N/A-79.7%$0.00$43.20MN/A70
CALA
Calithera Biosciences
N/AN/AN/AN/A$0.00N/AN/A60
CINGW
Cingulate
N/A$0.01
-22.6%		N/A-88.0%$0.00N/AN/A20
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SXTPW) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel